Predictors of Nodal Pathological Complete Response in Asian Women with Stage II-III Node-Positive Breast Cancer

被引:1
|
作者
Montagna, Giacomo [2 ,3 ,4 ]
Tong, Yiwei [1 ]
Ritter, Mathilde [3 ]
Levi, Jeremy [5 ]
Weber, Walter P. [3 ,4 ]
Chen, Xiaosong [1 ]
Shen, Kunwei [1 ]
机构
[1] Shanghai Jiao Tong Univ, Comprehens Breast Hlth Ctr, Dept Gen Surg, Ruijin Hosp,Sch Med, Shanghai, Peoples R China
[2] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY 10021 USA
[3] Univ Hosp Basel, Breast Ctr, Spitalstr 21, CH-4056 Basel, Switzerland
[4] Univ Basel, Basel, Switzerland
[5] Biometr Practice BIOP, Basel, Switzerland
关键词
NEOADJUVANT CHEMOTHERAPY; PREOPERATIVE CHEMOTHERAPY; AXILLARY DISSECTION; CONSERVING SURGERY; METASTASES; THERAPY; BIOPSY; IMPACT; CONSERVATION; TRASTUZUMAB;
D O I
10.1159/000513454
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Neoadjuvant chemotherapy (NAC) is increasingly used to treat node-positive (N+) breast cancer. Predictors of nodal pathological complete response (pCR) in Asian women are poorly described and there is variety in the management of the axilla after NAC. We evaluated predictors of nodal pCR and axillary management in a cohort of Asian N+ patients. Methods: Consecutive biopsy-proven N+ breast cancer patients treated with NAC were identified from the Shanghai Ruijin Hospital in China. Axillary lymph node dissection was performed on all patients, irrespective of the nodal response to NAC. Results: A total of 323 patients were included. Nodal pCR was achieved in 105 patients (33%), 15% of HR+/HER2- tumors, 38% of HR+/HER2+ tumors, 49% of HR-/HER2+ tumors, and 42% of HR-/HER2-tumors (p < 0.001). Factors associated with nodal pCR were (1) receptor status (HR+/HER2- [referent]: OR 3.42, 95% CI 1.43-8.16, p = 0.006 for HR+/HER2+; OR 4.19, 95% CI 1.85-9.50, p = 0.001 for HR-/HER2+; and OR 2.94, 95% CI 1.11-7.74, p = 0.029 for HR-/HER2-), (2) breast pCR (no pCR [referent]: OR 15.22, 95% CI 6.29-36.79, p < 0.001), and (3) absence of lymphovascular invasion (LVI [referent]: OR 9.04, 95% CI 2.09-39.18, p = 0.003). Conclusion: This study confirmed expected predictors of nodal pCR in Asian women and the benefit of NAC in downstaging the axilla independently of ethnicity.
引用
收藏
页码:359 / 364
页数:6
相关论文
共 50 条
  • [31] Rethinking the role of nodal status in TNM staging of node-positive breast cancer
    Anderson, S. J.
    Bryant, J. L.
    Jeong, J.
    Tang, G.
    Costantino, J. P.
    Mamounas, E.
    Geyer, C. E.
    Wolmark, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] The prognostic value of nodal ratios in node-positive breast cancer: AUBMC experience
    Shamseddine, A.
    Hatoum, H.
    Salem, Z.
    Khalek, Z. Abdel
    El Saghir, N.
    Taher, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] De-Escalation of Nodal Surgery in Clinically Node-Positive Breast Cancer
    Cabioglu, Neslihan
    Kocer, Havva Belma
    Karanlik, Hasan
    Gulcelik, Mehmet Ali
    Igci, Abdullah
    Muslumanoglu, Mahmut
    Uras, Cihan
    Mantoglu, Baris
    Trabulus, Didem Can
    Akguel, Giray
    Tukenmez, Mustafa
    Senol, Kazim
    Ozkurt, Enver
    Sen, Ebru
    Karadeniz Cakmak, Guldeniz
    Bademler, Suleyman
    Emiroglu, Selman
    Yildirim, Nilufer
    Kara, Halil
    Dag, Ahmet
    Dilege, Ece
    Altinok, Ayse
    Basaran, Gul
    Varol, Ecenur
    Ugurlu, Umit
    Bolukbasi, Yasemin
    Ersoy, Yeliz Emine
    Zengel, Baha
    Karaman, Niyazi
    Ozbas, Serdar
    Zer, Leyla
    Kilic, Halime Gul
    Agcaoglu, Orhan
    Sakman, Gurhan
    Utkan, Zafer
    Soyder, Aykut
    Akcan, Alper
    Ergun, Sefa
    Yilmaz, Ravza
    Aydiner, Adnan
    Soran, Atilla
    Ibis, Kamuran
    Ozmen, Vahit
    JAMA SURGERY, 2025,
  • [34] Axillary nodal management following neoadjuvant chemotherapy for node-positive breast cancer
    Ponce, Carolina
    Loza, Martin
    Mando, Pablo
    Pineiro, Africa
    Amat, Mora
    Costanzo, Victoria
    Nervo, Adrian
    Mysler, Daniel
    Nadal, Jorge
    Colo, Federico
    Loza, Jose
    Chacon, Reinaldo
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : 437 - 438
  • [35] COMPREHENSIVE TREATMENT OF STAGE II-III BREAST-CANCER
    KHARCHENKO, VP
    PANSHIN, GA
    SOTNIKOV, VM
    KHMELEVSKY, EV
    SOVETSKAYA MEDITSINA, 1985, (02): : 89 - 92
  • [36] For stage II node-positive breast cancer, is it worthwhile to consider adjuvant radiotherapy following mastectomy?
    Osman, Mohammed A. M.
    Elkady, Mohammad S.
    Nasr, Khalid E.
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [37] Adjuvant radiation therapy in stage III node-positive uterine cancer
    Schmid, Seraina
    Hsu, I-Chow
    Hu, Jessica M.
    Sherman, Alexander E.
    Osann, Kathryn
    Kapp, Daniel S.
    Chan, John K.
    GYNECOLOGIC ONCOLOGY, 2009, 115 (02) : 239 - 243
  • [38] Response to Paclitaxel in Node-positive Triple Negative Breast Cancer
    Ryu, Dong Won
    Lee, Chung Han
    JOURNAL OF THE KOREAN SURGICAL SOCIETY, 2010, 79 (03): : 173 - 179
  • [39] Nomogram for predicting axillary lymph node pathological response in node-positive breast cancer patients after neoadjuvant chemotherapy
    Wang Wenyan
    Wang Xin
    Liu Jiaqi
    Zhu Qiang
    Wang Xiang
    Wang Pilin
    中华医学杂志英文版, 2022, 135 (03) : 333 - 340
  • [40] Prognostic role of breast pathologic complete response after neoadjuvant chemotherapy in node-positive breast cancer patients
    Woo, J.
    Ryu, J. M.
    Lee, S. K.
    Yu, J.
    Lee, J. E.
    Kim, S. W.
    Nam, S. J.
    Chae, B. J.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S23 - S23